combinatorial delivery of multiple anticancer agents in a single novel therapeutic. This approach eliminates toxic carriers, permits safe dose-escalation and facilitates multi-drug deliver thereby maximizing the therapeutic index.

Initially, Co-D will focus solely on its lead product, Triolimus, to treat the rare malignancy angiosarcoma, breast cancer and non-small cell lung cancer (NSCLC). Preclinical studies demonstrate that their ability to eliminate toxic drug carriers while simultaneously delivering multiple synergistic drugs minimizes harmful side effects and maximizes therapeutic effects and strongly support advancement of this novel nano-medicine into human trials.

Triolimus combines three tried-and-true drugs (paclitaxel, rapamycin and 17-AAG). This strategy presents a relatively low research and development cost compared to the development of new chemical entities. Co-D will develop its lead product Triolimus under an orphan drug designation to treat angiosarcoma. Co-D’s long term goal is to seek approval to treat malignancies with known sensitivity to the agents incorporated in Triolimus (e.g. breast cancer, NSCLC). They anticipate that our product pipeline will grow as they advance through the development of Triolimus. They are dedicated to generating high value opportunities for patients and maximizing shareholders value.